Status:
COMPLETED
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under nat...
Eligibility Criteria
Inclusion
- Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
- Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator
Exclusion
- A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT00159770
Start Date
November 1 2001
End Date
September 1 2004
Last Update
February 21 2021
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aalborg, Denmark, 9100
2
Pfizer Investigational Site
Arhus C, Denmark, 8000
3
Pfizer Investigational Site
Augustenborg, Denmark, 6440
4
Pfizer Investigational Site
Ballerup Municipality, Denmark, 2750